Excision Bio licenses CRISPR technology from UC Berkeley
15-11-2017
CRISPR Therapeutics teams up with Massachusetts hospital in cancer treatment drive
23-08-2017
AndreyPopov / iStockphoto.com
The University of California (UC), Berkeley has filed a brief at the US Court of Appeals for the Federal Circuit in its appeal against a patent decision on the CRISPR/Cas9 technology.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
UC Berkeley, PTAB, CRISPR, MIT, Harvard, CRISPR/cas9, genetics, genome editing, Federal Circuit
